Clinical radioimmunodetection, 1978-1988: Overview and suggestions for standardization of clinical trials

Journal Article · Thu Feb 01 00:00:00 EST 1990 · Cancer Research; (USA)

OSTI ID:6994328

Larson, S M ^[1]

---

1. Memorial Sloan-Kettering Cancer Center, New York, NY (USA)

In the last decade of radioimmunodetection studies the radiolabeled antibody preparations used have gradually changed from polyclonal antibodies labeled predominantly with 131I to monoclonal antibodies labeled with diverse radionuclides including 131I, 111In, 123I, and 99mTc. Over this period progressive improvement in tumor imaging has been observed when one compares the best examples of early studies, performed with 131I labeled heterosera, to the best of modern images, obtained with 123I, 99mTc, or 111In labeled monoclonal antibodies. Important findings in 61 clinical studies reviewed include the reports from several centers which demonstrate occult disease in patients with carcinoma of colon, melanoma, and lymphoma, and the improved sensitivity and specificity of radioimmunodetection in comparison to transmission computerized tomography in the lymph nodes and abdomen, in lymphoma and colon cancer, and ovarian cancer. Evaluation of the liver remains a difficult problem with this technique and standard approaches are superior in most reports. The general principle of targeting radioactivity to tumor with radiolabeled antitumor antibody and the feasibility of developing practical clinical methodology which will add new diagnostic information have clearly been established. Toxicity, particularly for index studies, is reassuringly limited. In all the studies with surgical confirmation after i.v. injection, uptake in tumor is in the range of 0.005% injected dose/g tumor, and this low tumor uptake remains the single greatest limitation of the method. A second important problem is the prompt development of human anti-mouse antibody, which reduces the usefulness of follow-up studies. A serious criticism of the information currently available on radioimmunodetection is that the clinical studies reported to date vary greatly in approach and results. 95 references.

• OSTI ID: 6994328
• Journal Information: Cancer Research; (USA), Vol. 50; ISSN 0008-5472
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
MONOCLONAL ANTIBODIES
UPTAKE
NEOPLASMS
DIAGNOSIS
RADIOIMMUNOSCINTIGRAPHY
INDIUM 111
IODINE 123
IODINE 131
ISOMERIC NUCLEI
REVIEWS
SENSITIVITY ANALYSIS
SPECIFICITY
TECHNETIUM 99
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DIAGNOSTIC TECHNIQUES
DISEASES
DOCUMENT TYPES
ELECTRON CAPTURE RADIOISOTOPES
HOURS LIVING RADIOISOTOPES
INDIUM ISOTOPES
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
MINUTES LIVING RADIOISOTOPES
NUCLEI
ODD-EVEN NUCLEI
RADIOIMMUNODETECTION
RADIOISOTOPE SCANNING
RADIOISOTOPES
SCINTISCANNING
TECHNETIUM ISOTOPES
TRACER TECHNIQUES
YEARS LIVING RADIOISOTOPES
550601* - Medicine- Unsealed Radionuclides in Diagnostics